Bharat Biotech’s rotavirus oral vaccine introduced in Nigeria

ABLE Member, Bharat Biotech International Ltd (BBIL), a leading vaccine developer and manufacturer, announced that its rotavirus oral vaccine ROTAVAC has been introduced by Nigeria to immunize its children from the life-threatening diarrhoeal disease that affects millions of children worldwide. Nigeria currently accounts for 14% of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world. Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria. 

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “Decades of research and product development have resulted in ROTAVAC. This vaccine is now available in several countries across Asia, Africa, Latin America and the Middle East. We are proud to state that novel vaccines from India are saving lives worldwide.” We are committed to supporting, and reducing the infectious disease burden amongst children in the developing world, and to ensure nations like Nigeria in the African continent, have access to cost-effective world-class interventions for infants and vulnerable populations. ROTAVAC is safe and effective at preventing diarrheal disease caused by the Rotavirus.” 

ROTAVAC received WHO-Prequalification in January 2018. Bharat Biotech developed the first generation, rotavirus vaccine, Rotavac under a Public-Private Partnership with the Department of Biotechnology, Government of India and 16 other international partners, making it the largest ever social innovation project for public health. Bharat Biotech is a global leader in rotavirus vaccines, with one of the largest manufacturing capacities. The project was funded by the Govt of India, the Bill and Melinda Gates Foundation, Research Council of Norway, UK DFID, and Bharat Biotech. 

Nigeria introduces Bharat Biotech’s ROTAVAC vaccine for immunization in children

Recommended News